Novacyl
France 3 duplicate records merged Updated 9 July 2026
Novacyl is an API manufacturer based in France. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 24 November 2023 as VAI.
2
registered plants
2 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 24 November 2023 VAI US FDA
- 2 February 2023 VAI US FDA
- 2 March 2018 VAI US FDA
- 30 June 2016 VAI US FDA
- 4 July 2014 VAI US FDA
- 25 October 2012 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| France, France | 3009804152 |
| France, France | 3002807997 |
What they file, and where
| Molecule | Regulators | Docs |
| Salicylic Acid | PMDA (Japan) | 1 |
| アスピリン | PMDA (Japan) | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Novacyl comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 24 November 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates